

# *Journal of Pharmacological Sciences*

Published by The Japanese Pharmacological Society

## Notice to Contributors

(Effective from January 2008)

*Journal of Pharmacological Sciences (J Pharmacol Sci)* is an **international journal** intended for the advancement of pharmacological sciences in the world. The *Journal* welcomes submissions in all fields of experimental and clinical pharmacology, including neuroscience, and biochemical, cellular, and molecular pharmacology of the 17 subject categories described below, for publication as **Reviews, Full Papers, or Short Communications**. All papers are subjected to **peer-review**. Manuscripts will be published within 50 – 80 days after their acceptance.

**Submissions that have been published or accepted, or are under consideration for publication, with essentially the same content, will not be considered.** This restriction does not apply to results published as an abstract, letters to editors, or as submissions for symposia, provided that the submission adds significantly to the information available in the previously published submission.

**Manuscripts that reveal a lack of proper, ethical consideration for human subjects or experimental animals will not be accepted for publication.** The *Journal* endorses the [“Guiding Principles for the Care and Use of Laboratory Animals”](#) approved by The Japanese Pharmacological Society. Furthermore, we endorse the [“Recommendations from the Declaration of Helsinki”](#).

Authors are requested **to select one or two** (in their order of priority) **of the following subject categories** to which the manuscript applies. For any study employing natural medicine materials (NMM) (the details for NMM are described later in [the last paragraph of section 5. General Instructions](#)), be sure to include category No. 19 in your selection:

1. Biogenic active substances
2. Receptors/Channels/Transport systems
3. Intracellular signaling
4. Biochemical pharmacology
5. Peripheral nervous system pharmacology
6. Cardiovascular pharmacology/Hematology
7. Central nervous system pharmacology
8. Respiratory pharmacology
9. Renal pharmacology
10. Gastrointestinal pharmacology
11. Smooth muscle pharmacology
12. Bone and dental pharmacology
13. Endocrine pharmacology
14. Clinical pharmacology
15. Immunopharmacology/Inflammation
16. Chemotherapy

17. Toxicology

---

19. Natural medicine materials with significant biological activities

Authors are required to **suggest four reviewers** who would be the most pertinent to review the submitted paper. Authors may also indicate up to three reviewers that they would like excluded from the review process. The ultimate selection of such reviewers is at the sole discretion of the Editor.

---

### Preparation of Manuscripts

Papers should be in **standard English** and be prepared in A4 (210 mm × 297 mm) page size, using standard fonts with size of 11 or 12, with double-spacing, and margins of at least 25 mm all around (desirably, 25 lines per page). The authors must strictly adhere to the proper format of the *Journal* for all sections of the manuscript; refer to papers in recent issues for the general layout of the paper and also for details. For authors whose native language is not English, the *Journal* strongly recommends brushing up the English of the manuscript by consulting an English-speaking scientist before submission to avoid delays in receiving and processing of the manuscript.

#### 1. Full Papers

**1) Title page** - should include the complete title of the manuscript; full names of all authors; their affiliations and addresses; a running title of no more than 40 characters (including spaces); and the name and E-mail address of the corresponding author.

**2) Abstract and keywords** - 200 words presented in a concise form and including the purpose, general methods, findings, and conclusions of the research described in the paper. A list of 5 keywords or short phrases suitable for indexing should be typed at the bottom of the abstract page. Avoid vague or overly general terms. If necessary, the keywords will be adjusted to the standards of the *Journal* by the editors without consulting the authors.

**3) Introduction** - should give a short and clear statement of the relevant background and the rationale of the study.

**4) Materials and Methods** - should include explicit, concise descriptions of all new methods or procedures employed. Commonly used methods require only a citation of the original source. The description should be such that the reader can judge the accuracy, reproducibility, reliability, etc. of the work.

**5) Results** - should include experimental data but not extended discussions of its relative significance. Results are more easily grasped by readers if they are presented in graphic or tabular form rather than discursively. Data should not be repeated in the text, Tables, and Figures.

**6) Discussion** - should be pertinent to the results. Speculation is to be based on data only; be concise and clear. Lengthy discussions will necessarily mean a delay in accepting manuscripts for publication. The text should be written with a logical connection between the introduction and conclusions.

**7) References** - The format should be as described in [5. General Instructions](#).

**2. Short Communications** are completed projects of smaller scope, but may not be used for preliminary publications of the data; therefore, the same material cannot be published elsewhere as an original paper. The

main body of the text of these communications should be no more than 1,500 words in length, without any subheadings, and manuscripts should contain no more than 3 Figures and/or Tables and a maximum of 15 references. They should have an abstract not exceeding 100 words in length. The manuscripts normally occupy no more than 4 journal pages (e.g., about 12 typewritten pages including all components). Provide a short running title of no more than 40 characters (including spaces) in length and 3 keywords or short phrases for indexing (see [1. Full Papers](#)). Indicate the number of words used in the main body of the text. Please refer to [5. General Instructions](#) for references and other manuscript requirements.

**3. Reviews** will usually be written at the request of the *Journal*. Occasionally, unsolicited ones will be considered for publication; authors/organizers of such reviews should consult one of the editors, enclosing a one-page typed synopsis, before submitting the article. The unsolicited articles are subjected to rigorous assessment of their suitability for publication.

Five types of reviews will be considered: **1) Current Perspectives** (up to 10 typewritten pages for the main body of the text and a maximum of 30 references; they will normally occupy no more than 6 journal pages): These articles should provide insight into or comments on current directions of research on a topic and/or discuss potential new approaches to an area of investigation. **2) Critical Reviews** (up to 40 typewritten pages for the main body of the text and a maximum of 100 references): These should cover a current topic of interest that has not been recently reviewed, emphasizing a critical discussion of noteworthy developments in the field; they should not be just a compendium of studies on the topic and should not be only autobiographical. **3) Survey Reviews** (up to 60 typewritten pages for the main body of the text and a maximum of 300 references): Should be a comprehensive survey of the research on a topic that has not been recently reviewed. **4) Forum Minireviews** (no more than 30 journal pages): One set of reviews is put together by an organizer(s) on a particular topic; each set is composed of a maximum of 6 minireview articles (about 15 typewritten pages for all components of each manuscript, as a standard length; 4 – 5 journal pages, each) and a preface. The topic and contributors should be based on one of the Symposia of the Annual Meeting of The Japanese Pharmacological Society or they may be occasionally based on Symposia of special interest to pharmacologists. **5) New Drugs and Recent Techniques** (up to 60 typewritten pages for the main body of the text and a maximum of 300 references): The purpose of these reviews is to introduce worldwide recently developed drugs and new techniques. These articles should be written in sufficient scientific detail and format to explain the characteristics of the drugs and/or promising techniques evaluating pharmacological actions. The page charge for this type of Review is ¥12,600 per printed page.

Each manuscript should include an abstract, not exceeding 200 words, a running title of no more than 40 characters (including spaces) in length, and 5 keywords or short phrases for indexing (see [1. Full Papers](#)). Please refer to [5. General Instructions](#) for further details.

**4. Correspondence** (Letters to the Editor): The *Journal* will occasionally consider publishing letters to the editor from readers and authors in the "Correspondence" section. Letters should be comments and clarifications on articles that have recently been published in this *Journal* and be in a concise form. When necessary, please refer to [5. General Instructions](#).

## 5. General Instructions

**References** - should be cited in the text by number, in parentheses, in line with the text; the full reference is cited in a numbered list at the end of the paper. The reference list should be prepared with the authors' names (list all authors if six or less; otherwise, list the first six followed by et al.), full title of paper, journal, year of publication, volume, and initial and final pages.

e.g., Seki T, Ishimoto T, Sakurai T, Yasuda Y, Taniguchi K, Doi M, et al. Increased excretion of urinary 20-HETE in rats with cyclosporine-induced nephrotoxicity. *J Pharmacol Sci.* 2005;97:132 – 137.

References to books should include the author's name, title of article, editors, title of book, edition, city where the publisher is located, publisher, year of publication, and initial and final pages of the cited article or section.

e.g., Margineanu DG, Klitgaard H. Levetiracetam: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, editors. *Antiepileptic drugs*. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 419 – 427.

For formats of other published materials, please refer to the Vancouver style (see the "References" section in the *"Uniform Requirements for Manuscripts Submitted to Biomedical Journals"* <http://www.icmje.org/index.html>).

Papers are not to be cited as "in press" unless they have already been accepted for publication. In such cases, state the name of the journal and provide the accepted manuscript as supplemental material.

**Figures and Tables** - should be numbered consecutively with Arabic numerals, with each one displayed on a separate page. These usually will be reduced to fit a single column, 8.3-cm-wide, or at most, a double column, maximally 17.6-cm-wide. Please refer to a current issue of this *Journal* for general patterns. Any color Figure submitted by the author will be processed with the understanding that upon acceptance of the manuscript, the Figure will be published in color, with the cost of the reproduction being charged to the author.

**Abbreviations and Units** - While authors should avoid unfamiliar abbreviations, a limited number of clearly defined abbreviations may be used. Such abbreviations must be defined at the first mention in the text or defined in alphabetical order in a footnote on the first page. When in doubt, avoid unfamiliar abbreviations. For units, the *Journal* recommends the use of the International System of Units (SI Units). It is desirable to refer to standard abbreviations and units listed in the Instructions to Authors of the *Journal of Biological Chemistry* (<http://www.jbc.org/misc/ifora.shtml>).

**Drugs** - Generic names should be used in the text, Figures, and Tables.

**Guidelines for manuscripts concerning natural medicines** - Here, "natural medicines" mean any extract(s) or unpurified constituent(s) obtained from natural sources (natural medicine materials: NMM). Studies discussing NMM should comply with the [Guidelines/Checklist](#) of the *Journal* shown later; authors **MUST** provide the **completed** checklist for NMM upon manuscript submission. Manuscripts concerning simple screening of biological activities of the NMM and/or studies that do not meet the NMM guidelines stipulated in the Checklist for the NMM are **likely to be rejected without review**.

Consult the <a href="#">"Author's Checklist for Manuscript Submission"</a> that appears on the final page of these instructions for a more detailed explanation of the requirements on the manuscript preparation.
--

---

## Submission of Manuscripts

***J Pharmacol Sci* requires authors to submit all manuscripts online.** Manuscripts should be submitted at the J-STAGE (<http://www.jstage.jst.go.jp/browse/jphs/>) (<http://www.jstage.jst.go.jp/browse/jphs/-char/ja> for Japanese). We will not accept any manuscripts submitted as an E-mail attachment or by post.

Before entering the submission web site, please refer to this “Notice to Contributors” including “Author’s Checklist for Manuscript Submission” for overall guidelines for how your manuscript should be structured and formatted. Then, be sure to refer to and comply with the [“Instructions for Electronic Submission”](#), which will provide you with more detailed, technical, and other important information.

### Brief guidelines for electronic submission procedures (from January 2008)

- 1) Prepare the text (title page, abstract, main text, references, legends for Figures, and Tables) by MS-Word.
- 2) Prepare the Figures using applications that are capable of generating high-quality image (such as EPS or TIFF) files. The Figure number must be indicated on each Figure itself, outside the image area.
- 3) Save both text (all pages) and Figures as a single file in the PDF format (you may also make a PDF from multiple texts and images within the online system). File size must be smaller than 10 MB. When converting your file to the PDF format in your computer, activate the “Embed all the fonts” function. For the file name, use only one-byte alphanumeric characters; do not include colon, hyphen, slash, period (except for using in the extension), non-English characters, etc., and spaces. The users of Mac OS must put the extension **.pdf** at the end of the file name.
- 4) Login to the J-STAGE system. You are required to have your login ID. If you do not have one, you can easily get an ID by registering your e-mail address.
- 5) Start ‘New Submission’ and enter required information (manuscript type, subject category(s), title, abstract, supplemental information, four suggested reviewers, comments to the Editorial Office, etc.) into the web pages. During the process, you are required to upload the manuscript PDF file, or you can convert your texts and figures to PDF. You can also upload other supplemental items such as an “In Press” article to be referred to or appended data/information necessary for the manuscript such as papers discussing natural medicine materials, etc., if needed.

#### Notes:

- The submission system consists of 7 web pages for a new submission.
- During the submission process, you can save the items you have entered or uploaded, so that you will be able to resume the submission process at a later time.

---

**The editors** reserve the right to make minor revisions in manuscripts accepted for publication in the interest of clarity, consistency, and readability. However, they cannot accept responsibility for opinions expressed by contributors.

**The copyright** of the articles published in the *Journal* is transferred from the authors to the Publisher, The Japanese Pharmacological Society, upon acceptance of the manuscript.

**Charges** (the indicated price includes the consumption tax): A charge of ¥4,200 (four thousand two hundred Japanese Yen) per printed page will be made for all manuscripts, except for the Reviews on "New Drugs and Recent Techniques" (¥12,600 per printed page). Cost of color reproduction will be charged to the authors (¥63,000 per printed page consisting of one or more color pictures). All reprints are supplied at cost. Charges for English revision may be made if extensive rewriting is necessary.

**English script and rewrite** are under the supervision of S.M. Jung, Ph.D., Institute of Life Science, Kurume University, Kurume, Fukuoka, Japan.

**Editorial/Publishing Correspondence:**

JPS Editorial Office, Kinpodo Publishing Inc.

34 Nishiteranomae-cho, Shishigatani

Sakyo-ku, Kyoto 606-8425, Japan

TEL: +81-75-751-1111, FAX: +81-75-751-6859

E-mail: [journal@pharmacol.or.jp](mailto:journal@pharmacol.or.jp)

**Journal information:** <http://jps.pharmacol.org/>

**Abstract/Full text online and Electronic Submission "J-STAGE":**

<http://www.jstage.jst.go.jp/browse/jphs/> (issues after 2003 & E-Submission)

<http://www.jstage.jst.go.jp/browse/jjp/> (issues before 2002)



# *Journal of Pharmacological Sciences*

## **Author's Checklist for Manuscript Submission**

(Effective from January 2007)

Please consult the [“Notice to Contributors”](#) and complete the following checklist so that your manuscript will conform to the style and usage of the *Journal of Pharmacological Sciences* before submission.

### [ ] Title Page

- title: avoid using the trade name of a drug / should not contain abbreviations except for very standard ones / should indicate the experimental animal / a drug for which a generic name has not yet been given can be designated by a combination of letters and numbers only when accompanied by a specification of its pharmacological property (e.g., anti-allergic drug, AB-123)
- provide full names of all authors / provide affiliations and addresses of all authors / identify each author with the appropriate address by numerical superscripts
- provide information about the corresponding author
- provide a running title of no more than 40 characters and spaces
- indicate the number of words used in the main body of the text (Short Communication only)
- provide any necessary footnotes (e.g., change of address)

### [ ] Abstract Page

- limit Abstract to 200 words for Full Paper and Review, 100 words for Short Communication
- do not cite references in Abstract by reference numbers, but use full citation; omit the article title
- provide keywords: 5 items for Full Paper and Review, 3 items for Short Communication / avoid vague or overly general terms

### [ ] Text

- main- and subheadings: refer to current style in this *Journal*
- drug names: use generic names; if a generic name has not yet been given, provide the full chemical name at the first mention
- ionic charge should be shown throughout (e.g., Ca<sup>2+</sup> channel)
- provide names of sources including city, state (USA), and country (except for Japan) for experimental apparatuses, reagents, animals, and cell strains
- unpublished data, personal communication, etc. in the text: specify the source of the information (e.g., Y. Yamada et al., unpublished data)

### [ ] References -refer to current issues-

- list references in numerical order according to the first mention in the text
- "in press" citation must have been accepted for publication; designate journal title
- "unpublished observations", "personal communication", "submitted manuscript": do not list in "References", but insert in appropriate places in the text with source name
- "encyclopedia", "patent", and "thesis" are not valid reference citations

- state "(text in [specify language used] with English abstract)" for a paper with text written in languages other than English but with English abstract
- avoid citing any paper written in a language not normally used for international scientific publications (including Japanese) and does not have an English abstract; if you must cite such a reference, state your justification for including this reference, on a separate sheet; and specify the language in the reference list

[ ] Figures and their legends -refer to current issues-

- supply Figs. of sufficient quality for direct printing
- all figure elements (letters, numbers, and symbols, etc.) should be sufficiently large and clear so that they can be easily read after reduction
- in Fig. legends, do not use the pictorial representation of the actual graphic symbols themselves or actual patterns, but describe them in words (e.g., closed circle, dotted column) or commonly usable marks (e.g., \*, #); alternatively, give the explanations of symbols/patterns on the Figs., if representing them pictorially
- magnification of electronmicrographs should be indicated by a calibration bar on the photographs themselves to ensure that, after any necessary reduction, the scale is reduced in the correct proportion
- symbols indicating statistical significance: the number of symbols used to indicate a particular probability (*P* value) should be consistent throughout the manuscript; the same probability should be represented by the same number of symbols in the Figs. and Tables, and the number of symbols should increase as the *P* value decreases
- avoid unnecessary three-dimensional representation of data in bar graphs
- type legends for Figs. double-spaced on a separate page
- for a Fig. consisting of separate panels: do not provide a separate title for each panel, but rather provide one comprehensive title; explanations of panels to be provided in the legend following the title
- Any Fig. submitted in color will be printed "in color" / indicate desired final printing size / all color reproduction costs will be charged to the author

[ ] Tables and their footnotes -refer to current issues-

- type each Table double-spaced on a separate page; do not insert in the running text
- type a brief informative title above the Table and footnotes at the foot of the Table
- do not use vertical lines

---

[ ] Short Communication

- to determine if your study is appropriate for publication as a Short Communication, carefully read the [Notice to Contributors](#)
- type text without subdivision into sections
- Abstract of 100 words or less
- main body of the text of 1,500 words or less (on the title page, indicate the number of words used)
- no more than 15 references
- no more than 3 Figs. and/or Tables
- other manuscript requirements: see items shown above (from Title Page to Tables)